Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Other financing activities (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Other financing activities for 6 consecutive years, with $5.5 million as the latest value for Q4 2025.

  • Quarterly Other financing activities rose 555000.0% to $5.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.6 million through Dec 2025, up 35056.25% year-over-year, with the annual reading at $5.6 million for FY2025, 35056.25% up from the prior year.
  • Other financing activities for Q4 2025 was $5.5 million at Whitehawk Therapeutics, up from -$5.5 million in the prior quarter.
  • The five-year high for Other financing activities was $5.6 million in Q2 2025, with the low at -$5.5 million in Q3 2025.
  • Average Other financing activities over 4 years is $655555.6, with a median of $49000.0 recorded in 2023.
  • Peak annual rise in Other financing activities hit 555000.0% in 2025, while the deepest fall reached 32741.18% in 2025.
  • Over 4 years, Other financing activities stood at $99000.0 in 2022, then plummeted by 65.66% to $34000.0 in 2023, then tumbled by 102.94% to -$1000.0 in 2024, then surged by 555000.0% to $5.5 million in 2025.
  • According to Business Quant data, Other financing activities over the past three periods came in at $5.5 million, -$5.5 million, and $5.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.